# Why you stop losing weight on a GLP-1: plateaus explained

> Why weight loss slows and stops on a GLP-1: the physiology of a new set point, when a plateau is normal, and what's actually worth a clinician conversation.

**Evidence grade:** Supported but limited (rung 2 of 8 on the Peptide Evidence Ladder) · **Last reviewed:** 2026-06-30 · **Source page:** https://thepeptideera.com/evidence/glp1-plateau

## Short answer
A plateau is expected, not failure. In trials, weight loss slows and levels off as the body defends a new set point — resting metabolism falls and hunger hormones adjust. Most people on tirzepatide plateaued near 24 to 36 weeks; on semaglutide, loss continued for over a year and was levelling off near the end of the 68-week trial. A months-in stall means the drug did its work, not that it quit.

## Safety essentials worth knowing

These apply to GLP-1 and dual/triple-agonist medicines generally. They’re label-level points, not the full list, and not advice about you — your prescriber and the FDA label are the authority.

- **Pregnancy & breastfeeding:** these medicines are not recommended in pregnancy, and intentional weight loss is generally not advised in pregnancy; the labels advise stopping before a planned pregnancy. Breastfeeding status is a conversation to have with your clinician.
- **Birth control:** some of these medicines (such as tirzepatide) can make *oral* contraception less reliable. If you could become pregnant, ask about backup or non-oral contraception.
- **Thyroid boxed warning:** this drug class carries an FDA boxed warning (thyroid C-cell tumours seen in rodents) and is not for people with a personal or family history of medullary thyroid cancer (MTC) or MEN 2.
- **Blood sugar:** combined with insulin or a sulfonylurea, these medicines can cause low blood sugar — those other medicines often need prescriber-managed adjustment, not self-adjustment.
- **Eating disorders:** an appetite-suppressing medicine warrants particular caution with a current or past eating disorder; disclose this to your clinician.
- **Surgery, sedation & endoscopy:** because these medicines slow stomach emptying, tell your surgical or anaesthesia team you take a GLP-1 well in advance — they'll decide with you whether to continue or hold it (more: https://thepeptideera.com/evidence/glp1-and-surgery).

It is the single most-asked question in every GLP-1 community: *the scale stopped moving — is the medicine still working, or did I break it?* The honest, reassuring answer is that a plateau is the expected ending of the weight-loss curve, not a sign that anything has failed. This page explains why loss slows, what the trials show about *when* it tends to happen, and where the line sits between "normal" and "worth a conversation."

It describes; it does not prescribe. It contains no doses, no titration numbers, and nothing about changing how you take a medicine — those belong to the person who knows your history.

## Why does weight loss slow down and stop on a GLP-1?

**Because your body defends a new, lower set point — and the medicine was never going to override that physiology forever.** Weight loss is not a straight line down. As you lose weight, several well-documented systems push back at once.

The clearest is **metabolic adaptation**. When you lose weight, your resting metabolic rate falls — and it falls *more* than the smaller body alone would predict. A weight-reduced body becomes more energy-efficient, burning fewer calories at rest and during movement than it did before (Ravussin and colleagues). At the same time, hunger-side hormones shift: appetite-suppressing leptin drops while hunger signals rise. A GLP-1 medicine works *with* appetite, but it does not switch off this underlying biology.

The result is an energy balance that drifts back toward equilibrium. Early on, the appetite effect creates a large gap between intake and expenditure, and weight comes off quickly. Over months, expenditure falls and the body adapts until intake and output re-balance at a new, lower weight. That re-balancing *is* the plateau. Reaching it means the drug did its job and your body found a new steady state — not that the drug "stopped working."

## When does the plateau usually happen?

The trials give real numbers — and they differ by medicine and by starting body size.

| Medicine (trial) | Typical time the curve flattens | What the data show |
|---|---|---|
| **Tirzepatide** (SURMOUNT-1 analysis) | ~24–36 weeks | Median time to plateau ranged from about 24 weeks in those with the least excess weight to about 36 weeks in those with the most; by 72 weeks, roughly 88–90% had reached a plateau. |
| **Semaglutide** (STEP 1, 68-week trial) | near end of treatment | In the continuous 68-week trial, weight loss kept going for over a year and was levelling off near the end of treatment. |

Two takeaways. First, **the heavier you start, the later you tend to plateau** — there is simply more curve to travel. Second, **flattening is normal and universal**: in the tirzepatide analysis, nearly everyone reached a plateau by the trial's end, and they had still lost a great deal of weight. A plateau is where the trial *participants* ended up too.

## Is a plateau the same as the medicine "not working"?

No — and the STEP 4 trial draws the distinction cleanly. People who reached their plateau and **kept** taking semaglutide held onto their loss; those switched to placebo gradually **regained** weight. The medicine's ongoing job at a plateau is less about driving the number down and more about **holding the line against the biology that wants to push it back up.** A stable weight on treatment is the medicine working, not failing.

This is the heart of "is it still working?": people judge success by *continued loss*, when after several months the realistic measure becomes *successful defence* of the weight already lost.

## Normal plateau vs. worth a clinician chat

- **Normal:** the scale stalls after several months of steady loss; weight holds or drifts within a few pounds week to week; appetite and "food noise" are still well-controlled; you feel well.
- **Worth a conversation:** you plateaued very early and far from any reasonable goal; appetite and cravings have clearly come *back*; the scale is trending *up* over weeks, not just flat; or you reached your goal and want a plan for what maintenance looks like.

A plateau on its own is not a problem to "fix." A plateau *with* returning hunger, or steady regain, is a reason to talk it through — not a reason to change anything on your own.

## Frequently asked questions

**Did I plateau because I did something wrong?**
Almost certainly not. Plateaus happen to nearly everyone in the trials and reflect normal physiology — falling resting metabolism and shifting appetite hormones — plus the natural fact that a smaller body burns fewer calories. StatPearls notes the large majority of people lose-then-plateau.

**Will I lose more if I just wait?**
Sometimes the curve has more to give and patience is enough; often the plateau is the body's new steady state. The trials show most people settle at a plateau and stay near it. What happens next for *you* is an individual question for your clinician — not a number this page can predict.

**Does plateauing mean I should change my dose?**
That is not a question to answer from a website. Anything about how a medicine is taken is a clinician decision based on your full picture. This page deliberately gives no dosing guidance.

**If I stop now that I've plateaued, will the weight stay off?**
The maintenance evidence points the other way: in STEP 4, stopping led to gradual regain. Reaching a stable weight is the start of the maintenance conversation, not the end of it.

## Questions to ask a clinician

- Is my plateau where you'd expect for [how long I've been treated](/articles/how-long-glp1-takes-to-work) and where I started?
- Has my appetite or food-noise changed — and does that change the plan?
- What does "success" look like from here: more loss, or holding what I've lost?
- What's our maintenance plan — continue, adjust, or transition — and what are the criteria for each?
- Should we look at body composition or other markers, not just the scale number?

## Red flags / when to seek care

A plateau itself is not a medical emergency. These are separate symptoms that warrant prompt clinical contact regardless of the scale:

- **Steady, unexplained weight *regain* on treatment** alongside clearly returning hunger — worth reviewing the plan, not ignoring.
- **Severe or persistent abdominal pain**, especially radiating to the back with vomiting — seek care; this is not a plateau symptom.
- **Signs of dehydration or inability to keep fluids down** from ongoing GI symptoms.
- **New, severe, or frightening symptoms of any kind** — these are reasons to call, not data points to grade.

A stalled scale asks for perspective. The symptoms above ask for a clinician. Knowing which is which is most of the skill.

## Sources (5)
1. Horn et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials (Clinical Obesity 2025) — https://pubmed.ncbi.nlm.nih.gov/39800653/ [RCT]
2. Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021) — https://pubmed.ncbi.nlm.nih.gov/33567185/ [RCT]
3. Rubino et al. Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4, JAMA 2021) — https://pubmed.ncbi.nlm.nih.gov/33755728/ [RCT]
4. Ravussin, Smith & Ferrante. Physiology of Energy Expenditure in the Weight-Reduced State (Obesity 2021) — https://pmc.ncbi.nlm.nih.gov/articles/PMC8988211/ [REVIEW]
5. Sarwan, Daley & Rehman. Management of Weight Loss Plateau (StatPearls, NCBI Bookshelf 2024) — https://www.ncbi.nlm.nih.gov/books/NBK576400/ [REVIEW]

---
From The Peptide Era (https://thepeptideera.com) — evidence-graded, primary-sourced answers about GLP-1 medicines. Education, not medical advice. No doses, no sourcing.